Company intelligence / Profile preview

BioMediCan

Fremont, California, United Statesbiomedican.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has developed a biosynthesis platform that produces 99% pharmaceutical-grade cannabinoids that are bio-organic, non-GMO, and 70-90% less expensive than current market prices[1][4]

Modalities: Biosynthesized cannabinoids
Industry: Non-Drug Biotech

Drug pipeline

4 assets

CBG/CBGA

Pre-clinical

Indications: Inflammation, Pain, Nausea, Glaucoma

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioMediCan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMediCan.

Explore the full profile